openPR Logo
Press release

Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing Powerhouse

08-06-2025 08:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: BrandingBuzz.Agency
Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing

Acquisition marks the launch of Serotonin's buy-and-build strategy to consolidate digital marketing services at scale.
Image: https://www.globalnewslines.com/uploads/2025/08/281952c2eb2b091e8b4ac31ab1bb3267.jpg

Manchester, UK - Serotonin [https://www.serotonin.co.uk/] (www.serotonin.co.uk) has officially acquired Unparalleled, a digital agency known for its expertise in ecommerce and performance marketing.

The move creates a new force in the North West's marketing scene, with combined operations now generating in excess of 1 million in EBITDA annually. Unparalleled brings a team of 12 experts across to Serotonin increasing the total headcount within the agency to 32, with a plan to grow that to 40 by the end of 2025.

Serotonin selected Unparalleled for acquisition due to the agency's unique expertise in performance media and its proven ability to deliver exceptional ROI through advanced tools and data-led strategy. The company now plans to raise its first institutional funding round in Q1 2025 to accelerate growth and execute a targeted series of strategic acquisitions.

For Serotonin, known for working with large ecommerce clients like ASSOS of Switzerland, New & Lingwood and national property developers such as Legal & General and Grainger plc; this acquisition marks the beginning of a wider buy-and-build strategy aimed at consolidating best-in-class service providers under one roof.

Unparalleled brings deep expertise in ecommerce growth, having worked with high-performance brands such as The Private Clinic and Ebrands. Their strength in Google and Meta media buying, combined with their ability to leverage new technologies, significantly enhances Serotonin's paid media and digital strategy capabilities.

"This is a deliberate step forward in building a high-performance agency group, one that brings together specialist talent under a shared vision for performance, creativity and results. The acquisition of Unparalleled further strengthens our position in a fragmented market, forecasts our EBITDA for 2025 at over 1mln, and expands our capabilities where it counts. Serotonin was already a serious player, now we're moving faster, going bigger, and focussed on scaling through smart, strategic moves." - Dom Carter [https://www.linkedin.com/in/djvcarter], CEO Serotonin

"The core principle behind Unparalleled was to provide high-growth brands with a strategic advantage through more intelligent and profitable marketing. Integrating with Serotonin allows us to apply this vision on a grander scale. This acquisition marks the creation of a new agency model-one built for agility, strategic acquisitions, and optimised for rapid growth." - Luke Bielby [https://www.linkedin.com/in/lukebielby/], Former CEO Unparalleled, Chief Commercial Officer Serotonin

Serotonin was expertly advised by leading corporate law firm Pannone Corporate LLP, whose strategic legal guidance was instrumental to the successful completion of the transaction.

About Serotonin

Serotonin is a full-service agency for global businesses that want to grow better, faster. Founded by Dom Carter and Clair Heaviside in 2019, Serotonin partners with ambitious brands to scale ecommerce channels through paid media, data strategy, and creative excellence.

From its Manchester studio, Serotonin supports clients across the UK, Europe, and the US. Notable clients include: ASSOS of Switzerland, British Cycling, Blacklock, New & Lingwood, Belier, and SUDU.

Serotonin were listed in The Prolific North Top 50 Digital Agencies 2025 and have previously won Best Mid-Size Agency and Best Small Agency awards. Co-founder Clair Heaviside was named Businesswoman of the Year in 2023, one of NatWest's Top Ten Female Entrepreneurs to Watch and Northern Gamechanger in 2025. CEO Dom Carter was listed as Tech Pioneer in the BIMA 100 and named Digital, Media & Creative Professional of the Year by Manchester Young Talent Awards, and Young Marketing & Media Professional 2022 by Insider Media

To find out more, contact Dom directly at dom@serotonin.co.uk or visit serotonin.co.uk [https://serotonin.co.uk/]
Media Contact
Company Name: Serotonin
Contact Person: Dom Carter
Email: Send Email [http://www.universalpressrelease.com/?pr=serotonin-acquires-unparalleled-to-create-1m-ebitda-marketing-powerhouse]
Phone: 07805897192
Address:25 Dale Street, 5th Floor, Manchester
City: Greater Manchester, M1 1EY
State: GB
Country: United Kingdom
Website: https://www.serotonin.co.uk/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Serotonin Acquires Unparalleled to Create 1m+ EBITDA Marketing Powerhouse here

News-ID: 4135970 • Views:

More Releases from Getnews

Luxo Living Introduces Chocolate Brown Norah Boucle Sofa Collection and Sculptural Concrete Coffee Tables
Luxo Living Introduces Chocolate Brown Norah Boucle Sofa Collection and Sculptur …
Australian furniture retailer expands product range with premium seating solutions and artistic concrete tables featuring handcrafted designs for modern homes. Image: https://www.globalnewslines.com/uploads/2025/08/7bfdbd485d0806b30e936e0b4a8499da.jpg Luxo Living, a leading online furniture retailer in Australia, has launched its new Norah 5-Seater Boucle Sofa Set in Chocolate Brown alongside the organic sculptural Concrete Coffee Table collection this month. The expanded product range targets Australian homeowners seeking premium furniture combining contemporary aesthetics with functional design for living spaces. The
Sweet Southern Charm Announces Expansion of Fashion Offerings in Colonial Heights
Sweet Southern Charm Announces Expansion of Fashion Offerings in Colonial Height …
Image: https://www.globalnewslines.com/uploads/2025/08/1756476656.jpg Sweet Southern Charm, a locally cherished fashion destination, has announced an exciting expansion of its product lines to meet increasing demand for unique styles in the region. Known for its warm atmosphere and carefully curated collections, the boutique continues to attract both loyal customers and new visitors seeking high-quality fashion in Colonial Heights. The recent expansion includes an even wider range of apparel, accessories, and seasonal collections designed to appeal
NFL M.O.M.S. Hosts
NFL M.O.M.S. Hosts "The Next Play Networking Mixer" to Show How Listening Can Sa …
NFL M.O.M.S. hosts The Next Play Networking Mixer Sept. 6 in Hampton, GA-bringing athletes, moms, and community leaders together around one core theme: the power of truly listening. The event, held during National Suicide Awareness Month, will explore how listening with empathy can break silence, prevent tragedy, and prepare families for life beyond sports. Image: https://authoritypresswire.com/wp-content/uploads/2025/08/NFL-M.O.M.S.-Erica-Wilson.jpeg Hampton, GA - The Mothers of Motivated Sons (NFL M.O.M.S.) will host The Next Play Networking
Mike Milligan, Founder of 1 Oak Financial Interviewed on the Influential Entrepreneurs Podcast Discussing Retirement CHI
Mike Milligan, Founder of 1 Oak Financial Interviewed on the Influential Entrepr …
Image: https://authoritypresswire.com/wp-content/uploads/2025/08/Mike_Milligan__1_-removebg-preview.png Mike Milligan discusses the concept of your retirement CHI Listen to the interview on the Business Innovators Radio Network: https://businessinnovatorsradio.com/interview-with-mike-milligan-founder-of-1-oak-financial-discussing-your-retirement-chi/ Mike Milligan, the founder of 1 Oak Financial. He delved into the concept of "Retirement Chi," a term that Mike has trademarked, which emphasizes the importance of building a personal vision for retirement that goes beyond mere financial planning. Mike explained that while many retirees focus on investments and financial security, they

All 5 Releases


More Releases for Serotonin

Serotonin Supplement Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Serotonin Supplement Market- (By Functionality (Depression Relief, Insomnia Relief, Appetite Gaining, Mood Disorder Treatment, Weight Loss, and Cognitive Health Improvement), By Form (Tablets / Pills, Capsules, Liquid, Powder/ Chewable and Others), By Sales Channel (Hypermarkets / Supermarkets, Specialty Stores, E-commerce, Drug Stores & Pharmacies, Health & Wellness Stores, Convenience Stores, Departmental Stores and Others), By
Serotonin Supplement Market Know the Scope and Trends
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Serotonin Supplement Market- (By Functionality (Depression Relief, Insomnia Relief, Appetite Gaining, Mood Disorder Treatment, Weight Loss, and Cognitive Health Improvement), By Form (Tablets / Pills, Capsules, Liquid, Powder/ Chewable and Others), By Sales Channel (Hypermarkets / Supermarkets, Specialty Stores, E-commerce, Drug Stores & Pharmacies, Health & Wellness Stores, Convenience Stores, Departmental Stores and Others), By
Global Antidepressants Drugs Market Size - By Product Type(Tricyclic Antidepress …
Antidepressants Drugs Market Insights: Trends, Drivers, and Outlook 2024 - 2031 Antidepressants Drugs Market Scope: Unveiling Today's Trends Antidepressant drugs are medications designed to alleviate symptoms of depression and mood disorders. The global antidepressants market has been witnessing significant growth, driven by increasing awareness and diagnosis of mental health issues, along with a rising prevalence of depression and anxiety disorders. As healthcare systems prioritize mental health, the demand for effective pharmacological treatments
Serotonin-Dopamine Activity Modulators Market Insights, Forecast to 2031
The report extensively examines the global Serotonin-Dopamine Activity Modulators market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Serotonin-Dopamine Activity Modulators . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the
Global Serotonin Syndrome Market Size, Status and Forecast 2019-2025
Market Research Report Store offers a latest published report on Serotonin Syndrome Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. The report contains 158 pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability. Click to view the full report TOC, figure and tables: https://www.marketresearchreportstore.com/reports/632687/global-serotonin-syndrome-market-size-status   Serotonin syndrome is a group of symptoms
04-06-2017 | Health & Medicine
TMR
Global Serotonin-norepinephrine Reuptake Inhibitors Market Future Outlook 2024
Serotonin-norepinephrine reuptake inhibitors (SNRIs) or dual - uptake inhibitors represent one of the newest but important classes of antidepressants, which are commonly prescribed for anxiety disorders and depression therapeutic treatment. SNRIs were first launched in the international markets in 1993, when the U.S. FDA approved first of its kind Venlafaxine (Effexor) as an antidepressant, which would help treat numerous individuals suffering from varying anxiety disorders and/or depression. Browse Market Research Report